Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -73.80

Roquefort Therapeutics plc Net Cash Used Provided By Financing Activities is USD -73.80 for the year ending December 31, 2023, a -100.00% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Roquefort Therapeutics plc Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 3.75 M, a -40.15% change year over year.
  • Roquefort Therapeutics plc Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 6.26 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Vaccines Venture Capital
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

February 6, 2025

Any question? Send us an email